Search clinical trials for: LUM001

Total 76 results

Mirum Pharmaceuticals, Inc.

Withdrawn

An Open-label Study to Evaluate the Long-term Safety and Tolerability of LUM001 in Patients With Primary Biliary Cirrhosis (CASCADE)

Primary Biliary Cirrhosis

United States, United Kingdom
Mirum Pharmaceuticals, Inc.

Completed

Open Label Study to Evaluate Safety and Efficacy of LUM001 in Patients With Primary Sclerosing Cholangitis (CAMEO)

Primary Sclerosing Cholangitis (PSC)

United States, United Kingdom, Canada
Mirum Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of LUM001 (Maralixibat) With a Drug Withdrawal Period in Participants With Alagille Syndrome (ALGS) (ICONIC)

Alagille Syndrome

France, Belgium, Poland, Australia, Spain, United Kingdom
Mirum Pharmaceuticals, Inc.

Completed

Open Label Study to Evaluate Efficacy and Long Term Safety of LUM001 (Maralixibat) in the Treatment of Cholestatic Liver Disease in Patients With Progressive Familial Intrahepatic Cholestasis (INDIGO)

Progressive Familial Intrahepatic Cholestasis (PFIC)

United States, United Kingdom, Poland, France
Mirum Pharmaceuticals, Inc.
Childhood Liver Disease Research and Education Network

Completed

Evaluation of LUM001 in the Reduction of Pruritus in Alagille Syndrome (ITCH)

Alagille Syndrome

United States, Canada
Mirum Pharmaceuticals, Inc.

Completed

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Subjects With Alagille Syndrome (ALGS) (IMAGINE)

Alagille Syndrome

United Kingdom
Mirum Pharmaceuticals, Inc.
Lumena Pharmaceuticals, Inc.; Childhood Liver Disease Research and Education...

Completed

An Extension Study to Evaluate the Long-Term Safety and Durability of Effect of LUM001 in the Treatment of Cholestatic Liver Disease in Pediatric Subjects With Alagille Syndrome (IMAGINE-II)

Alagille Syndrome

United States, Canada
Mirum Pharmaceuticals, Inc.

Completed

Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille Syndrome (IMAGO)

Alagille Syndrome

United Kingdom
Nuvamid SA
Medpace, Inc.; Anapharm; LGD

Active, not recruiting

Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants

Healthy Volunteers

United States
Mirum Pharmaceuticals, Inc.

Active, not recruiting

A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). (RISE)

Cholestatic Liver Disease | Alagille Syndrome | Progressive Familial Intrahepatic Cholestasis

United States, United Kingdom, France, Belgium, Poland, Brazil, Mexico
Mirum Pharmaceuticals, Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Maralixibat in Subjects With Progressive Familial Intrahepatic Cholestasis (MARCH-PFIC) (MARCH-PFIC)

Progressive Familial Intrahepatic Cholestasis (PFIC)

Italy, United States, Argentina, France, Singapore, United Kingdom, Austria, Brazil, Mexico, Lebanon, Germany, Turkey, Poland, Belgium, Canada, Colombia, Hungary
LGD
ProRelix Services LLP

Recruiting

Safety and Efficacy of Orally Administered NUV001 Nutraceutical Supplement in Sickle Cell Disease Patients

Sickle Cell Disease

India
Mirum Pharmaceuticals, Inc.

Completed

Evaluation of Maralixibat in Biliary Atresia Response Post-Kasai (EMBARK)

Biliary Atresia

United States, United Kingdom, China, Taiwan, Germany, Poland, Singapore, Vietnam
Mirum Pharmaceuticals, Inc.

Active, not recruiting

MRX-800: A Long-Term Safety Study of Maralixibat in the Treatment of Cholestatic Liver Disease in Subjects Who Previously Participated in a Maralixibat Study (MERGE)

Cholestatic Liver Disease

United States, France, United Kingdom, Canada, Belgium, Poland, Australia, Spain
Shanghai Pharmaceuticals Holding Co., Ltd

Recruiting

Efficacy and Safety of LT3001 on Treating the Acute Ischemic Stroke

Acute Ischemic Stroke

China
Mirum Pharmaceuticals, Inc.

Completed

Phase 2 Study to Evaluate LUM001 in Combination With Ursodeoxycholic Acid in Patients With Primary Biliary Cirrhosis (CLARITY)

Primary Biliary Cirrhosis | PBC

United States, United Kingdom, Canada
Mirum Pharmaceuticals, Inc.

Completed

Study to Assess the Relative Potency of Multiple Oral Doses of LUM001 and SHP626 in Overweight and Obese Adults as Assessed by Fecal Bile Acid Excretion

Healthy Volunteers

United States
Baliopharm Pty Ltd

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Atrosimab (ATM001) in Healthy Volunteers

Healthy Volunteers

Australia
David Kirsch
American Society of Clinical Oncology

Completed

Cathepsin Activatable Fluorescent Probe (LUM015)

Sarcoma | Soft Tissue Sarcoma | Breast Cancer

United States
Symphogen A/S
Swedish Orphan Biovitrum

Completed

Open Label Trial on the Safety and Efficacy of Sym001 in the Treatment of Immune Thrombocytopenic Purpura (ITP)

Immune Thrombocytopenic Purpura

United States, Belgium, Germany, India, Israel, Poland, Romania, Russian Federation, Serbia, Spain, Ukraine, United Kingdom
Novartis Pharmaceuticals

Recruiting

Extension Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension Participants

Pulmonary Arterial Hypertension

Spain, Germany, Netherlands, Poland, United Kingdom, Argentina, United States
Peking Union Medical College Hospital
Beijing Immupeutics Medicine Technology Limited

Recruiting

Safety and Efficacy of IPM001 in Patients With Advanced Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Zhuhai Trinomab Pharmaceutical Co., Ltd.

Not yet recruiting

A Trial to Evaluate the Efficacy and Safety of TNM001 for the Prevention of Lower Respiratory Tract Infection Caused by Respiratory Syncytial Virus in Infants

Respiratory Syncytial Virus Infections

China
Liveome Inc.

Recruiting

A Study of LIV001 in Healthy Subjects and Those With Mild-to-Moderate Active Ulcerative Colitis (UC)

Ulcerative Colitis

Australia
Trinomab Biotech Co., Ltd.

Recruiting

A Study of TNM001 in Chinese Healthy Preterm and Term Infants

Respiratory Syncytial Virus Infections

China
Laekna Limited

Suspended

A Study on the Safety and Efficacy of LAE001 in the Treatment of Metastatic Prostate Cancer

Prostate Cancer Metastatic

China
Novartis Pharmaceuticals

Active, not recruiting

Study of Efficacy and Safety of LTP001 in Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

United States, Spain, Germany, Poland, United Kingdom, Netherlands, Argentina
Lexeo Therapeutics
Weill Medical College of Cornell University; Alzheimer's Drug Discovery Foundation

Active, not recruiting

Gene Therapy for APOE4 Homozygote of Alzheimer's Disease

Alzheimer Disease | Early Onset Alzheimer Disease

United States
Lumosa Therapeutics Co., Ltd.

Unknown

Study to Investigate the Safety of LT5001 Drug Product for Uremic Pruritus in Hemodialysis Patients

Uremic Pruritus

Taiwan
Lexeo Therapeutics

Recruiting

Long-Term Follow-up of Gene Therapy for APOE4 Homozygote Alzheimer's Disease (LEADLTFU)

Alzheimer Disease

United States
AmDerma

Completed

Study Comparing AM001 Cream to Vehicle in the Treatment of Plaque Psoriasis

Skin Diseases | Skin Diseases, Papulosquamous | Plaque Psoriasis

United States
Lumosa Therapeutics Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of Multiple Doses of LT3001 Drug Product in AIS Subjects (BRIGHT)

Acute Ischemic Stroke
Lumosa Therapeutics Co., Ltd.

Not yet recruiting

A Study to Evaluate the Safety and Efficacy of LT3001 Drug Product in Subjects AIS Undergoing EVT

Acute Ischemic Stroke
Lumicell, Inc.
National Cancer Institute (NCI)

Completed

Intraoperative Detection of Residual Cancer in Breast Cancer

Breast Cancer

United States
Lumosa Therapeutics Co., Ltd.

Unknown

A Study to Evaluate the Safety and Potential Efficacy of LT3001 Drug Product in Subjects With AIS

Acute Ischemic Stroke

Taiwan, United States
Guangzhou Patronus Biotech Co., Ltd.
Yantai Patronus Biotech Co., Ltd.

Active, not recruiting

Safety and Immunogenicity of COVID-19 Vaccine in Population Aged 18 Years and Above

COVID-19

China
LGD
Assistance Publique Hopitaux De Marseille; CEN Biotech; Etablissement Français...

Recruiting

Effect of NUV001 Supplementation in Patients Suffering From Sickle Cell Disease (SCD)

Sickle Cell Disease

France
Purinomia Biotech, Inc.

Recruiting

Safety of PUR001 Monotherapy in Patients With Advanced Solid Tumors

Advanced Solid Tumors

United States
Lumicell, Inc.
National Cancer Institute (NCI)

Recruiting

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer

United States
Lumicell, Inc.
National Cancer Institute (NCI); Massachusetts General Hospital; Dana-Farber...

Completed

Feasibility Study of Intraoperative Imaging in Breast Cancer

Breast Cancer

United States
Guangzhou Patronus Biotech Co., Ltd.
Afﬁliated Hospital of North Sichuan Medical College; Yantai Patronus Biotech...

Active, not recruiting

The Immunogenicity and Safety Following a Heterologous Booster Dose of Recombinant SARS-CoV-2 Vaccine LYB001

COVID-19 | Vaccine Reaction

China
Huashan Hospital
Peking University People's Hospital; Beijing Immupeutics Medicine Technology...

Not yet recruiting

Safety and Efficacy of Autoimmune Cell Therapy for Patients With Hepatocellular Carcinoma

Hepatocellular Carcinoma

China
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

The Phase Ⅱ/Ⅲ Trial of LYB001

COVID-19
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

A Phase Ⅰ Trial to Evaluate the Safety and Immunogenicity of SARS-CoV-2 Vaccine LYB001

COVID-19
Yantai Patronus Biotech Co., Ltd.

Not yet recruiting

Phase Ⅱ and Ⅲ Trial of a SARS-CoV-2 Vaccine LYB001

COVID-19
Elucida Oncology
Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL)

Withdrawn

ELU001 in Pediatric Subjects Who Have Relapsed and/or Refractory CBFA2T3-GLIS2-positive AML (Pediatric AML)

Acute Myeloid Leukemia | AML, Childhood | Relapsed Pediatric AML | Refractory Pediatric AML
HuniLife Biotechnology, Inc.

Recruiting

A Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, and Immunogenicity of HuL001

Idiopathic Pulmonary Fibrosis

Taiwan
Hadassah Medical Organization

Completed

Efficacy of Sialic Acid GNE Related Thrombocytopenia (SA-thrombo)

Thrombocytopenia
Karolinska Institutet
deFair Medical AB

Active, not recruiting

Probiotics for Weight Loss

Overweight

Sweden
Elucida Oncology

Recruiting

A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)

Ovarian Diseases | Ovarian Neoplasms | Ovarian Cancer | Ovarian Epithelial Cancer | Fallopian Tube Cancer | Endometrial Neoplasms | Endometrial Cancer | Endometrial Clear Cell Adenocarcinoma | Ovarian Carcinoma | Endometrial Adenocarcinoma | Peritoneal Cancer | Endometrioid Adenocarcinoma | Ovarian Adenocarcinoma | Ovarian Serous Adenocarcinoma and other conditions

United States

Search clinical trials for: LUM001

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Canada

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations